INTRANASAL ADMINISTRATION OF ADENO-ASSOCIATED VIRUS TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS

Last updated:

Abstract:

A method to prevent, inhibit or treat one or more symptoms associated with disease of the central nervous system by intranasally, intrathecally, intracerebrovascularly or intravenously administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease, in an amount effective, e.g., to provide for cross-correction.

Status:
Application
Type:

Utility

Filling date:

12 Jan 2022

Issue date:

7 Jul 2022